MARKET

ELTX

ELTX

Elicio Therapeutics, Inc.
NASDAQ
2.409
-0.001
-0.06%
Opening 13:31 09/08 EDT
OPEN
2.420
PREV CLOSE
2.410
HIGH
2.460
LOW
2.340
VOLUME
190.51K
TURNOVER
--
52 WEEK HIGH
16.00
52 WEEK LOW
2.340
MARKET CAP
63.30M
P/E (TTM)
-1.1059
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ELTX last week (0831-0904)?
Weekly Report · 1d ago
Weekly Report: what happened at ELTX last week (0824-0828)?
Weekly Report · 08/31 09:54
Weekly Report: what happened at ELTX last week (0817-0821)?
Weekly Report · 08/24 09:54
Analysts Offer Insights on Healthcare Companies: Obsidian Therapeutics (OBX), Elicio Therapeutics (ELTX) and Aethlon Medical (AEMD)
TipRanks · 08/18 10:30
Analysts Offer Insights on Healthcare Companies: Elicio Therapeutics (ELTX), EyePoint Pharmaceuticals (EYPT) and LeonaBio (LONA)
TipRanks · 08/17 12:30
Weekly Report: what happened at ELTX last week (0810-0814)?
Weekly Report · 08/17 09:55
Elicio Therapeutics GAAP EPS of -$0.43 beats by $0.11
Seeking Alpha · 08/13 20:53
Press Release: Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Dow Jones · 08/13 20:01
More
About ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.

Webull offers Elicio Therapeutics Inc stock information, including NASDAQ: ELTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELTX stock methods without spending real money on the virtual paper trading platform.